Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | Director | May 01, 2024 | May 01, 2024 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 19, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date May 01, 2024 · Filed May 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2034-04-30 | Direct | 40,000 |
Reported balance
After 2024-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.
MACROGENICS INC
Report date May 19, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,750 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19 | Direct | 22,000 |
Reported balance
After 2026-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F3: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
F3: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
APPLIED GENETIC TECHNOLOGIES CORP
Report date November 30, 2022 · Filed December 01, 2022
Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Other · Disposed 34,246 · Balance 0 F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2023-09-18 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-30 · Disposition to issuer · Disposed 14,285 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2024-03-26 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-30 · Disposition to issuer · Disposed 9,375 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.83 · Expires 2024-12-29 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-30 · Disposition to issuer · Disposed 4,688 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.06 · Expires 2025-11-19 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-30 · Disposition to issuer · Disposed 6,200 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.75 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-30 · Disposition to issuer · Disposed 8,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2028-07-25 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2028-11-15 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2029-12-04 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-12-16 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-30 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2031-11-30 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-11-30 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.
F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001587514-26-000009 · wk-form4_1779307998.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-19 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001587514-26-000009 · wk-form4_1779307998.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| February 15, 2026 Filed Feb 17, 2026 23:22 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 21,165 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001587514-26-000007 · wk-form4_1771370533.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: On February 15, 2023, the reporting person was granted 127,000 restricted stock units. Eighty-four thousand, six hundred seventy (84,670) were vested prior to the reporting person's separation from the company and 21,165 units vested upon his separation on August 13, 2025 in accordance with his Separation Agreement. F1 · derivative.expiration_date: On February 15, 2023, the reporting person was granted 127,000 restricted stock units. Eighty-four thousand, six hundred seventy (84,670) were vested prior to the reporting person's separation from the company and 21,165 units vested upon his separation on August 13, 2025 in accordance with his Separation Agreement. Read SEC document |
| February 15, 2026 Filed Feb 17, 2026 23:22 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 21,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001587514-26-000007 · wk-form4_1771370533.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 867,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023, the reporting person was granted 127,000 restricted stock units. Eighty-four thousand, six hundred seventy (84,670) were vested prior to the reporting person's separation from the company and 21,165 units vested upon his separation on August 13, 2025 in accordance with his Separation Agreement. Read SEC document |
| February 08, 2026 Filed Feb 10, 2026 23:17 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 15,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001587514-26-000004 · wk-form4_1770765435.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,832 Underlying: Common Stock · 15,831 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into the Company's stock on a one-for-one basis. F2 · derivative.exercise_date: On February 8, 2024, the reporting person was granted 95,000 restricted stock units. One-third of the restricted stock units vested after one year and one-half of the remaining units vested pursuant to the reporting person's "Separation Agreement" on August 13, 2025. The remaining units vest in two equal installments on the anniversary of the grant date. F2 · derivative.expiration_date: On February 8, 2024, the reporting person was granted 95,000 restricted stock units. One-third of the restricted stock units vested after one year and one-half of the remaining units vested pursuant to the reporting person's "Separation Agreement" on August 13, 2025. The remaining units vest in two equal installments on the anniversary of the grant date. Read SEC document |
| February 08, 2026 Filed Feb 10, 2026 23:17 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 15,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001587514-26-000004 · wk-form4_1770765435.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 846,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 21:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 31,664 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001587514-25-000005 · wk-form4_1755291908.xml · derivative · entry 4 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,663 Underlying: Common Stock · 31,664 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting. F1 · derivative.expiration_date: Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 21:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 21,165 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001587514-25-000005 · wk-form4_1755291908.xml · derivative · entry 3 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,165 Underlying: Common Stock · 21,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting. F1 · derivative.expiration_date: Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 21:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 31,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001587514-25-000005 · wk-form4_1755291908.xml · nonDerivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting. F2 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 21:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 21,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001587514-25-000005 · wk-form4_1755291908.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 798,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting. F2 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:28 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 42,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000035 · wk-form4_1740000523.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,330 Underlying: Common Stock · 42,329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023 the reporting person was granted 127,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023 the reporting person was granted 127,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023 the reporting person was granted 127,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:28 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 42,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000035 · wk-form4_1740000523.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 777,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023 the reporting person was granted 127,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:28 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 31,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000015 · wk-form4_1739323682.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,327 Underlying: Common Stock · 31,673 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 8, 2024 the reporting person was granted 95,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 8, 2024 the reporting person was granted 95,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 8, 2024 the reporting person was granted 95,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:28 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantCommon Stock | 31,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000015 · wk-form4_1739323682.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,086 F1 · price: On February 8, 2024 the reporting person was granted 95,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 20:26 UTC | MACROGENICS INC MGNX · Entity 6104 | GiftCommon Stock | 53,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-24-000155 · wk-form4_1728505591.xml · nonDerivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · The Koenig 2024 Irrevocable Trust Disclosed balance after: 427,480 F1 · price: Transfer is a gift which the reporting person believes was, in whole or in part, exempted by Rule 16a-13 as a change in form of beneficial ownership and the reporting person disclaims beneficial ownership of shares held by the irrevocable trust except to the extent of his pecuniary interest therein. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 20:26 UTC | MACROGENICS INC MGNX · Entity 6104 | GiftCommon Stock | 53,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-24-000155 · wk-form4_1728505591.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Transfer is a gift which the reporting person believes was, in whole or in part, exempted by Rule 16a-13 as a change in form of beneficial ownership and the reporting person disclaims beneficial ownership of shares held by the irrevocable trust except to the extent of his pecuniary interest therein. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:35 UTC | MACROGENICS INC MGNX · Entity 6104 | GiftCommon Stock | 374,215 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-24-000153 · wk-form4_1727296509.xml · nonDerivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · The Koenig 2024 Irrevocable Trust Disclosed balance after: 374,215 F1 · price: Transfer is a gift which the reporting person believes was, in whole or in part, exempted by Rule 16a-13 as a change in form of beneficial ownership, and the reporting person disclaims beneficial ownership of shares held by the irrevocable trust except to the extent of his pecuniary interest therein. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:35 UTC | MACROGENICS INC MGNX · Entity 6104 | GiftCommon Stock | 374,215 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-24-000153 · wk-form4_1727296509.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 703,413 F1 · price: Transfer is a gift which the reporting person believes was, in whole or in part, exempted by Rule 16a-13 as a change in form of beneficial ownership, and the reporting person disclaims beneficial ownership of shares held by the irrevocable trust except to the extent of his pecuniary interest therein. Read SEC document |
| May 01, 2024 Filed May 1, 2024 20:30 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-24-011872 · form4-05012024_080541.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:04 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 42,341 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000040 · wk-form4_1708470288.xml · derivative · entry 3 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,659 Underlying: Common Stock · 42,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023 the reporting person was granted 127,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023 the reporting person was granted 127,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023 the reporting person was granted 127,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:04 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 14,349 | $17.40 | $249,672.60 |
DisclosureSEC source: 0001125345-24-000040 · wk-form4_1708470288.xml · nonDerivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,077,628 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:04 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 42,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000040 · wk-form4_1708470288.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,091,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023 the reporting person was granted 127,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:31 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000019 · wk-form4_1707777099.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:31 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 248,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001125345-24-000019 · wk-form4_1707777099.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,000 Underlying: Common Stock · 248,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:10 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | Exercise / conversionStock option (right to buy) · Derivative | 21,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-23-033675 · doc4.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires 2032-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vested on May 18, 2023 and are fully exercisable. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:10 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | Exercise / conversionCommon Stock | 21,000 | $0.60 | $12,600.00 |
DisclosureSEC source: 0001209191-23-033675 · doc4.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:24 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-23-031456 · doc4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares underlying this option vest on May 19, 2024, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:32 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 127,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000037 · wf-form4_167666948789460.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,000 Underlying: Common Stock · 127,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:32 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 510,000 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001125345-23-000037 · wf-form4_167666948789460.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,000 Underlying: Common Stock · 510,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:13 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | Exercise / conversionStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-23-005471 · doc4.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vested on May 18, 2022 and are fully exercisable. Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:13 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | Exercise / conversionCommon Stock | 10,500 | $2.55 | $26,775.00 |
DisclosureSEC source: 0001209191-23-005471 · doc4.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,000 | Not disclosed Strike: $2.17 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 11 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2031-11-30 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $4.72 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 10 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-12-16 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $3.02 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 9 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-12-04 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $6.90 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 8 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-11-15 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $4.25 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 7 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-07-25 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,000 | Not disclosed Strike: $7.75 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 6 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2027-02-28 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,200 | Not disclosed Strike: $16.06 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 5 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,200 shares Expires 2025-11-19 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,688 | Not disclosed Strike: $20.83 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 4 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,688 shares Expires 2024-12-29 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,375 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 3 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,375 shares Expires 2024-03-26 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,285 | Not disclosed Strike: $4.90 | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,285 shares Expires 2023-09-18 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | OtherCommon Stock | 34,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023024 · form4.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. F1 · price: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:19 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-031007 · doc4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 16, 2022 Filed May 17, 2022 21:20 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 53,265 | $1.51 Strike: $1.51 | $80,430.15 |
DisclosureSEC source: 0001125345-22-000049 · wf-form4_165282239043395.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,265 shares Expires 2023-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| May 16, 2022 Filed May 17, 2022 21:20 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 53,265 | $1.51 | $80,430.15 |
DisclosureSEC source: 0001125345-22-000049 · wf-form4_165282239043395.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The transaction represents an exercise and hold of options. The shares are jointly owned with reporting person's spouse. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:47 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 480,000 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001125345-22-000029 · wf-form4_164575004704334.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:52 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001062993-21-012055 · form4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-11-30 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over one year from the date of grant. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:49 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036376 · doc4.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:49 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036376 · doc4.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:03 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 280,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000026 · wf-form4_161420779282904.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.